Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3484356 in Chinese Patients With ER+, HER2- Advanced Breast Cancer
NCT05509790Phase 1Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2022
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of imlunestrant in breast cancer (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Pharmacokinetics: Plasma Concentration of LY3484356. Started Oct 2022; status: active, not recruiting.
02
Drugs
imlunestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05509790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05509790.